The rise and rise of superbugs is a growing health issue. The article, Alarm at Spread of Superbugs beyond Hospitals by Amy Corderoy [30 Apr 2012 published SMH], discusses the growing antibiotic resistance problems and spread of superbugs outside of hospitals and into the community.
"The state and federal governments are so concerned by the rise in infections they have commissioned an expert group to try to stop it, the Herald has learnt," said Corderoy.
The collaboration between Phylogica and Medlmmune sits directly in this space. Medlmmune is a world leader in the development of novel biological drugs to treat infectious diseases.
There is no doubt that phylomer peptides are an amazing new source for novel biological drugs. Well, obviously there is some doubt as the MC for PYC is only $25m. Nonetheless, the Watch this Space mantra could well apply to future deals and collaborations in relation to antibiotic discovery. Its worth reprising this quote from the recent Nick Woolf interview on Wholesale Investor;
"We've got primary hits that are more effective, have better antibiotic activity than their marketed products [amoxicillin]," said Woolf.
PYC Price at posting:
4.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)